logo
Breakthroughs in HIV

Breakthroughs in HIV

WebMD3 days ago
It's been over 40 years since the emergence of HIV. It's killed hundreds of thousands of Americans, and millions of people globally. Those numbers would be even higher without medical breakthroughs.
Let's talk about some of them.
In 1996, Highly Active Antiretroviral Therapy (HAART) was developed. It suppresses the virus from replicating and attacking your immune system, which lowers your viral load and increases the CD4 (white blood cells that fight infections for your immune system). That reduces your risk of opportunistic infections and extends your life expectancy.
The decrease in viral load makes HIV less transmissible and helps reconstitute your immune system, but it took a while before it was known by how much This was a major breakthrough in HIV treatment and prevention. But it was hardly the first.
Perhaps the first big break came in 1983, when scientists isolated the virus that pinpointed the cause of AIDS. This revolutionized the understanding of AIDS — where it was, how it works, and how to combat it.
Then in 1985, the first HIV blood test was licensed. This was a breakthrough of sorts, because it allowed the virus to be detected before it was too late. But there was still no treatment. That came in 1987 when AZT was developed.
AZT was the first antiretroviral treatment for HIV-AIDS.
It helped and prevented mother-to-child transmission of the virus. But it had serious side effects. I've heard horrible stories from AZT survivors, but it was all that was available at the time.Until 1996, when HAART changed everything. By 1997, it was the standard of care for new HIV cases.
In 2012, it was discovered that providing HIV medication to HIV-negative people at high risk for the virus could prevent transmission, with an incredible success rate. This is called pre-exposure prophylaxis or PrEP. It was meant to be another amazing breakthrough in science.
For the first time, there was a proven method of preventing HIV transmission. The implications included ending transmission of HIV, and ending the HIV-AIDS epidemic. But PrEP hasn't been widely accepted by the public, mostly due to stigma associated with HIV and LGBTQ people.
So we're yet to achieve those goals.
The year 2016 changed my life more than any other. I was at a conference in Florida where Bruce Richman spoke about U=U. It played a huge role in my decision to become an HIV advocate. I've been an ambassador for U=U ever since.
What is U=U? Undetectable equals Untransmittable means that when you take HIV medication as prescribed, you can achieve an undetectable viral load. This means there's not enough virus in your blood to be counted.
What happens to the virus? Small amounts of it can survive but remain harmlessly dormant in your body, in small amounts known as reservoirs. The virus can't be transmitted sexually or mother to child.
People who live with HIV can safely have children with no risk of transmission to their partner or baby. This revelation was monumental and it's changed lives. It was a breakthrough in understanding.
In 2021, there came the first long-acting injectable. It was a breakthrough for those who struggled with pill fatigue or forgetfulness. Pill fatigue is a common problem, especially because there's also stigma associated with simply taking meds for HIV.
I remember learning about injectable HIV medication at a conference called CROI (Conference on Retroviruses and Opportunistic Infections). It's a scientific event that attracts leading experts who discuss research and findings for collective understanding. I've attended the conference twice as a community liaison and learned so much about HIV research and the experts doing it.
I learned about the potential for longer acting treatments, and about research exploring different methods of delivery, from injectable treatments to the possibility of implants. I can tell you that even a few years ago, research for a cure of HIV-AIDS was getting really exciting.
I truly believe we're close to finding a cure. Now is not the time to kill funding dedicated to this research.
I've talked about a lot of breakthroughs in HIV. This year, that list of breakthroughs adds another big advancement.
In 2025 the FDA approved a drug that can be injected twice yearly, once every 6 months. It can also be used as PrEP, which has also been approved. That's incredible!
You don't have to remember to take meds every day, carry meds with you, or be seen taking them.
I hold on to hope that one day one of these breakthroughs will change public perception of HIV. There's no reason to fear this virus as long as you have access to the medicine.
The stigma of HIV is antiquated. It's based on a mysterious disease that was a certain death sentence and only affects gay men But none of this is true anymore.
HIV is no longer the deadly disease it once was. With incredible advancements, there's no excuse for fear or stigma to exist. HIV today is nothing more than a chronic condition that's easily managed, and only getting better with time.
I believe we're close to a cure. I just learned that researchers have found a way to awaken dormant HIV cells. I find that extremely exciting and wonder if it could lead to a cure. If dormant cells can be awakened, then targeted and killed, that could be a cure. It's so exciting that we're getting closer, so it's no time for defunding HIV research and prevention efforts.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cutting mRNA Research Could Be Our Deadliest Mistake Yet
Cutting mRNA Research Could Be Our Deadliest Mistake Yet

Time​ Magazine

time5 hours ago

  • Time​ Magazine

Cutting mRNA Research Could Be Our Deadliest Mistake Yet

The U.S. Department of Health and Human Services (HHS) recently announced it will wind down funding for mRNA vaccine development—which could prove to be one of the costliest, deadliest decisions HHS Secretary Robert F. Kennedy Jr. will make during his tenure. HHS has already scaled back access to and recommendations for COVID-19 vaccines—a decision experts are deeply concerned about—and Kennedy's frequently misinformed views on vaccines continue to fan the flames of anti-vaccination attitudes. Now, Kennedy's failure to fully explore the potential of mRNA vaccines could stagnate research that has the potential to save millions of lives around the world. The dark cloud of COVID-19, one of the deadliest infectious disease outbreaks in history, can hardly be thought of as having a silver lining. But the nearest thing to a glimmer of a positive would be that the fast development of COVID-19 vaccines helped prevent many more deaths and led to rapid progress in our understanding and use of mRNA technology. This greater understanding is now being explored as potential preventions or therapies for a wide range of diseases, from H5N1 bird flu and HIV to cancer. Terminating 22 mRNA projects will not only directly set back research on mRNA vaccines for infectious diseases including flu; it will also arguably have negative knock-on effects for researchers the world over exploring personalized treatments for noncommunicable diseases like cancer. Early research on some novel uses of mRNA is promising. For example, a preliminary trial of an mRNA HIV vaccine found that 80% of participants generated neutralizing antibodies, which in theory could help block HIV—pending further research and development. A melanoma mRNA vaccine, when combined with existing treatment, reduced the risk of death or disease recurrence by nearly 50%. (The vaccine is currently being tested further in a full scale Phase 3 clinical trial). Even more amazingly, personalized vaccines—where vaccines are created specifically for an individual using information from their cancer to optimize their immune response—using mRNA technology have even been proposed as a universal vaccine adaptable for all cancers. Read More: The CDC Shooting is a Dark Sign for Science and America Much of the research on personalized mRNA cancer vaccines is in some way indebted to gains in knowledge made from COVID-19 research, and it stands to reason that pulling such a large amount of funding from mRNA projects will slow down further progress in these areas. Approximately $500 million worth of research funding would almost certainly have advanced the scientific community's fundamental understanding of how, and to what extent, mRNA technology works and how it could be applied to prevent and fight disease. Also problematic is the manner in which HHS under Kennedy conveys their decisions. In announcing the funding withdrawal, HHS states it 'will focus on platforms with stronger safety records and transparent clinical and manufacturing data practices.' This implies that mRNA vaccines have not been properly or transparently tested—which is not true. The safety of COVID-19 mRNA vaccines has been demonstrated in numerous studies and systematic evidence reviews. Like pretty much all vaccines and treatments, mRNA vaccines are not without side effects, but evidence shows that any adverse events are nearly always mild and short-lived. COVID-19 vaccines have already saved millions of lives globally, with mRNA vaccines accounting for a significant majority of all doses administered in many countries. Kennedy's claim that 'mRNA technology poses more risk than benefits' is almost farcical in light of scientific evidence. Moreover, the whole purpose of clinical research is to test whether new scientific innovations—like novel applications of mRNA into different diseases—are safe and effective in the first place. Kennedy has long spoken of how we need more evidence and testing on mRNA vaccines, and so it is painfully ironic that he is pulling funding for research which would enable the scientific community to do just that. Read More: An mRNA Melanoma Vaccine Shows Promise Perhaps most concerning is the caliber of evidence upon which decisions with such massive implications are being made. In an HHS announcement of the termination of mRNA projects, Kennedy claims 'the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu.' The truth is, initial vaccines and booster doses have been shown to be very effective against reducing infection, hospitalization, and death from COVID-19. Kennedy does not even provide links or citations to systematic reviews or meta-analyses in reputable journals, the gold standard methods for scientific evidence. Rather, he simply links to an online evidence review which cherry picks studies searching only for the harms—and not the overall safety, effectiveness, or cost-benefit analysis—of the mRNA vaccines. The report does not describe the methods used to select and review studies, nor does it appear itself to have been peer-reviewed by other scientists. It almost certainly wouldn't be publishable in a scientific journal, yet it is being used as evidence to justify the fate of half a billion dollars of research funds. This is another example of how fringe viewpoints on mRNA technology, instead of the best available scientific evidence, are under Kennedy and HHS becoming the new mainstream. The U.S. has been at the forefront of developing mRNA technology for the past few decades, from the Nobel Prize-winning research of professors Katalin Kariko and Drew Weissman at the University of Pennsylvania on mRNA, to the key role of U.S.-based pharmaceutical companies in vaccine production and rollout. Perhaps other countries, companies, and funding sources will offset this funding loss and lead the development of mRNA vaccine innovations. Large investments are already being made in the U.K. and China, for example. That would be to the detriment of U.S. scientific innovation and progress. Kennedy is right to scrutinize the potential overreach of the pharmaceutical industry, and to ensure their research and development is ethical and transparent. However, his seemingly personal war against "Big Pharma" and ideological opposition to mRNA risks stunting research that could one day help prevent the next pandemic or even provide cures for hitherto incurable cancers.

D-Dimer Test Flags Clot Risk, Aids Broader Diagnosis
D-Dimer Test Flags Clot Risk, Aids Broader Diagnosis

Time Business News

time17 hours ago

  • Time Business News

D-Dimer Test Flags Clot Risk, Aids Broader Diagnosis

D Dimer Test is a kind of blood test detecting the presence of D-dimer in the blood. D-dimer is a protein fragment of fibrin formed after Fibrinolysis degradation of blood clot. It is helpful to diagnose the conditions with abnormal blood clots formation and breakdown, intravascular fibrinolysis, and coagulation. High D-dimer levels indicate clinical suspicion of a blood clot and needs ultrasound, CT angiography, scans could be performed to confirm the presence of clot and location of clot. D-Dimer test is not specific to any disease. D-Dimer test is not specific to any disease and thus is performed in conjunction with other evaluations and diagnostic tests. 0.5 is measured as normal range for D-dimer and greater than 0.5 is measured to be positive. D-dimer decreases under abnormal medical case which is measured by specific antibodies. Key Growth Drivers and Opportunities Demand for D-Dimer Testing: Traditional testing is replaced by D-dimer testing, allowing for faster test results, quicker diagnosis, shorter patient wait times, and better patient outcomes overall. D-Dimer testing to be more widely used by customers offering compelling advantages. Moreover, the growing prevalence of lung and cardiovascular illnesses might, in extreme circumstances, lead to potentially fatal blood clot problems, which propels D-Dimer Test. Rising Genetic Disorders: Increasing cases of Thrombus embolism along with various cardiovascular and pulmonary diseases that could be life threating due to clot formation increases the demand for D-Dimer Test globally. D-dimer functions as valuable marker in various clinical conditions such as HIV, atrial fibrillation, coronary artery disease. New technological advancement such as development of aptamers, reducing use of antibodies for D-dimer testing being cost-effective, long-lasting boosts D-Dimer Test widening scope for these tests. Challenges The major challenge consists of inadequate skilled professionals and trained professionals unable to perform the test properly and lack of knowledge leads to false results and restrains the D-Dimer test Market. High cost and poor reimbursement policies restrains people to take such tests for proper diagnosis increasing the prevalence of disease and deaths. Innovation and Expansion Study Links Long COVID Brain Fog to Blood Microclots In September 2023, Finding was published in Nature Medicine, suggesting links between brain fog in long COVID and 'micro clots' in the blood. These clots often contain misfolded fibrinogen proteins that prevent the clots from breaking down, and this effect can clog blood vessels and block oxygen flow to the brain and other organs. Blood tests for both D-dimer and fibrinogen are already standard around the world, so researchers had plenty of available data to check whether the same phenomenon occurred in other groups of patients. LumiraDx Expands Rapid Testing for VTE and Heart Failure In June 2022, LumiraDx Limited, a next-generation point of care Diagnostics Company, announced its cardiovascular offering with a CE Mark for its new NT-proBNP test to aid in the diagnosis of CHF and an updated CE Mark for its D-Dimer test to now rule out venous thromboembolism (VTE) in symptomatic patients. With these two additions, the LumiraDx Platform can further support clinicians in quickly and accurately assessing patient symptoms for both VTE and heart failure at the point of care. The LumiraDx NT-proBNP test is a rapid microfluidic immunofluorescence assay for the quantitative measurement of NT-proBNP in human capillary, venous whole blood and plasma specimens. Inventive Sparks, Expanding Markets The major companies present in the D-dimer test market are Bio/Data Corporation, Becton Dickinson BV, Sysmex Corporation, Abbott Laboratories, Inc., Dickinson and Company, Hoffman-La Roche Ltd., among others. Global companies work to foster lasting innovation, grow their markets, and provide quality goods and services. They concentrate on improving customer experience, applying tech, and creating strong operations. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS

Flesh-eating bacteria case in Cape Cod prompts public health alert: What to know
Flesh-eating bacteria case in Cape Cod prompts public health alert: What to know

USA Today

time19 hours ago

  • USA Today

Flesh-eating bacteria case in Cape Cod prompts public health alert: What to know

A warning from the Massachusetts Department of Public Health may have some beachgoers exercising a little more caution as they try to escape the August heat. Residents and visitors at Buzzards Bay, a community on the south end of Cape Cod, are on alert after officials identified a person with a rare, flesh-eating bacterial infection in the area. Officials said the bacteria, known as Vibrio, could pose a risk to others in nearby coastal waters. The Vibrio species, which includes Vibrio vulnificus, can cause severe and life-threatening infections. Some can lead to necrotizing fasciitis, which kills off flesh around an open wound. Many people with a Vibrio vulnificus infection can get seriously ill and need intensive care or limb amputation. About 1 in 5 people with this infection die, sometimes within a day or two of becoming ill. But it's not the first time this bug has made its way to the Massachusetts bay: In a news release, the department of health said there have been seven cases of the illness over the last seven years among residents of the commonwealth, including four who were exposed in Massachusetts. The Vibrio bacteria and the infection it causes are usually more common in warmer waters, including in the Gulf Coast states of Louisiana, Texas and Florida, Dr. Larry Madoff told USA TODAY. But it's increasingly being seen northeastern states along the Atlantic coast, he added, such as Massachusetts and New York. "It's associated with warmer waters, and our waters are getting warmer," said Madoff, adding that the area where it's been found, Buzzards Bay, is an area with estuaries, small islands and warmer water on the western area of Cape Cod. The Vibrio bacteria also thrive in salty and brackish waters along the Atlantic coast, said Madoff, medical director for the Massachusetts Department of Public Health's Bureau of Infectious Disease and Laboratory Sciences. Above-average water temperatures are creating the conditions that allow the bacteria to grow, especially in the spring, summer and early autumn. Still, he said, there's no need for most people to worry, as long as they take certain precautions. "I would not discourage people from going to the beach," he said. "The beach is good and people need to cool off." What precautions should people take against flesh-eating bacteria? There are several species of Vibrio bacteria that can cause people to fall seriously ill. So how can people protect themselves? The bacteria is opportunistic, and it can enter the body through open wounds, health officials said. Foods like contaminated shellfish can also carry the bacteria. People with health conditions including liver disease, cancer, diabetes, HIV or who are on immunosuppressants are at highest risk of severe illness from the bacteria following exposure. Some precautions include: What are some symptoms and signs of flesh-eating bacterial illness? According to the U.S. Centers for Disease Control and Prevention, common signs of a Vibrio infection include diarrhea, stomach cramps, nausea, vomiting, fever, chills, dangerously low blood pressure and blistering lesions. Wounds that become infected may be red, swollen or discolored and may have a discharge.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store